• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Beyond Air Inc.

    12/13/24 4:25:32 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care
    Get the next $XAIR alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on December 13, 2024

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    BEYOND AIR, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   47-3812456

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    900 Stewart Avenue, Suite 301

    Garden City, NY

      11530
    (Address of Principal Executive Offices)   (Zip Code)

     

    Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan

     

    Inducement Stock Option Award

     

    (Full title of the plans)

     

    Steven A. Lisi

    Chairman and Chief Executive Officer

    Beyond Air, Inc.

    900 Stewart Avenue, Suite 301

    Garden City, NY 11530

    (Name and address of agent for service)

     

    (516) 665-8200

    (Telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Gregory Sichenzia

    Avital Perlman

    Sichenzia Ross Ference Carmel LLP

    1185 Avenue of the Americas, 31st Floor

    New York, NY 10036

    (212) 930-9700

     

    Adam Newman

    Beyond Air, Inc.

    General Counsel

    900 Stewart Avenue, Suite 301

    Garden City, NY 11530

    (516) 665-8200

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 6,000,000 shares of common stock of Beyond Air, Inc. (the “Registrant”), par value $0.0001 per share (the “Common Stock”), issuable pursuant to the Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan (the “Amended Plan”). The contents of the previous Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) for the Amended Plan on October 4, 2018 (File No. 333-227697), May 13, 2020 (File No. 333-238239) June 30, 2021 (File No. 333-257562) and December 20, 2023 (File No. 333-276171), to the extent not otherwise amended or superseded by the contents hereof, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

     

    Inducement Award

     

    This Registration Statement is also being filed for the purpose of registering shares of Common Stock issuable upon the exercise of a stock option award granted to David Webster, the Chief Commercial Officer of the Registrant, to induce such individual to accept employment with the Registrant (the “Inducement Award”). The Inducement Award was granted effective as of July 8, 2024 and is exercisable for the purchase of 125,000 shares of Common Stock.

     

    The Inducement Award was approved by the Registrant’s Compensation Committee of the Board of Directors in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The Inducement Award was granted outside of the Amended Plan.

     

     
     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    As permitted by the rules of the Commission, this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the Amended Plan or the Inducement Award, as applicable, as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents of the Registrant filed with the Commission are incorporated by reference in this Registration Statement as of their respective dates:

     

      (a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, filed with the Commission on June 24, 2024;
         
      (b) the Registrant’s Quarterly Reports on Form 10-Q for quarterly periods ended June 30, 2024 and September 30, 2024, filed with the Commission on August 6, 2024 and November 12, 2024, respectively;
         
      (c)

    the Registrant’s Current Reports on Form 8-K filed with the Commission on June 18, 2024, June 27, 2024 (except as to any portion furnished under Item 2.02), August 9, 2024, September 27, 2024, October 2, 2024, October 9, 2024, November 6, 2024, November 18, 2024 (except as to any portion furnished under Item 2.02), November 26, 2024, December 3, 2024 and December 6, 2024; and

         
      (d)

    the description of the Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on May 3, 2019, as updated by Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended March 31, 2022, including any amendments or reports filed for the purpose of updating such description.

     

    All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act of 1934, as amended (the “Exchange Act”) but prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the Commission.

     

    For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     
     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Incorporated in the State of Delaware, the Registrant is subject to the Delaware General Corporation Law (the “DGCL”). Section 145 of the DGCL empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation) by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. A corporation may indemnify such person against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may, in advance of the final disposition of any civil, criminal, administrative or investigative action, suit or proceeding, pay the expenses (including attorneys’ fees) incurred by an officer or director in defending such action, provided that the director or officer undertakes to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the corporation.

     

    A Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor under the same conditions, except that no indemnification is permitted without judicial approval if such person is adjudged to be liable to the corporation. Where a present or former officer or director is successful on the merits or otherwise in the defense of any action, suit or proceeding referred to above, the corporation must indemnify him or her against the expenses (including attorneys’ fees) which he or she actually and reasonably incurred in connection therewith.

     

    The indemnification and advancement of expenses provided above is not deemed to be exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any corporation’s bylaws, agreement, vote of stockholders or disinterested directors or otherwise.

     

    The Registrant’s Amended and Restated Certificate of Incorporation authorizes the Registrant to provide indemnification of (and advancement of payments to) its directors, officers and agents (and any other persons to which applicable law permits the Registrant to provide indemnification) to the full extent required or permitted by applicable law.

     

    The Registrant’s Amended and Restated Bylaws (“Bylaws”) provide that the Registrant shall indemnify its directors and executive officers (“executive officers” shall have the meaning defined in Rule 3b-7 promulgated under the Exchange Act) to the extent not prohibited by the DGCL or any other applicable law; provided, however, that the Registrant may modify the extent of such indemnification by individual contracts with its directors and executive officers; and, provided, further, that the Registrant shall not be required to indemnify any director or executive officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the Registrant, (iii) such indemnification is provided by the Registrant, in its sole discretion, pursuant to the powers vested in the Registrant under the DGCL or any other applicable law or (iv) such indemnification is required to be made under section 44(d) of the Bylaws.

     

    The Registrant has entered into indemnification agreements with each of its directors and our executive officers and has obtained insurance covering its directors and officers against losses and insuring the Registrant against certain of its obligations to indemnify its directors and officers.

     

     
     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit Number   Description
    4.1   Amended and Restated Certificate of Incorporation of AIT Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as amended and filed with the Commission on March 15, 2017).
         
    4.2   Amended and Restated Bylaws of AIT Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on 8-K, as amended and filed with the Commission on March 15, 2017).
         
    4.3   Certificate of Amendment of Amended and Restated Certificate of Incorporation, dated June 25, 2019 (incorporated herein by reference to Exhibit 3.3 to the Registrant’s Annual Report on Form 10-K filed with the Commission on June 28, 2019).
         

    4.4

     

    Second Certificate of Amendment of Amended and Restated Certificate of Incorporation, dated November 22, 2024 (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 26, 2024).

         
    4.5   Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, as amended and filed with the Commission on March 15, 2017).
         
    5.1*   Opinion of Sichenzia Ross Ference Carmel LLP
         
    10.1*  

    Beyond Air, Inc. Seventh Amended and Restated 2013 Equity Incentive Plan.

         
    10.2*   Form of Stock Option Agreement (Inducement Grant).
         
    23.1*  

    Consent of Marcum LLP, independent registered public accounting firm.

         
    23.2*  

    Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1).

         
    24.1*   Power of Attorney (included on signature page of Registration Statement).
         
    107*   Filing Fee Table.

     

    * Filed herewith.

     

     
     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Garden City, New York, on December 13, 2024.

     

      BEYOND AIR, INC.
         
      By: /s/ Steven Lisi
        Steven Lisi
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Beyond Air, Inc., hereby severally constitute and appoint Steven Lisi and Adam Newman, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Beyond Air, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Steven Lisi  

    Chairman and Chief Executive Officer

    (Principal Executive Officer)

      December 13, 2024
    Steven Lisi        
    /s/ Douglas Larson  

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      December 13, 2024
    Douglas Larson        
             
    /s/ Ron Bentsur   Director   December 13, 2024
    Ron Bentsur        
             
    /s/ Robert Carey   Director   December 13, 2024
    Robert Carey        
             
    /s/ William Forbes   Director   December 13, 2024
    William Forbes        
             
    /s/ Yoori Lee   Director   December 13, 2024
    Yoori Lee        
             
    /s/ Erick Lucera   Director   December 13, 2024
    Erick Lucera        

     

     

     

     

    Get the next $XAIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XAIR

    DatePrice TargetRatingAnalyst
    7/17/2025$11.00Buy
    D. Boral Capital
    6/25/2024Buy → Neutral
    BTIG Research
    7/28/2023$10.00Overweight
    Piper Sandler
    6/15/2023$15.00Buy
    BTIG Research
    11/12/2021$12.00 → $16.00Buy
    Truist Securities
    More analyst ratings

    $XAIR
    SEC Filings

    View All

    Beyond Air Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    2/2/26 4:05:40 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Beyond Air Inc.

    S-3 - Beyond Air, Inc. (0001641631) (Filer)

    1/30/26 4:01:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Beyond Air, Inc. (0001641631) (Filer)

    1/20/26 4:30:36 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

    BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early sta

    4/1/25 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

    First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ:XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round.

    3/24/25 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

    The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe primary objective of the Phase 1b study is to assess preliminary efficacy by objective response rate (ORR) and duration of response (DOR) per RECIST version 1.1 and secondarily immune-related response via iRECISTThe study will recruit patients from four sites across Israel HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an imm

    12/3/24 4:05:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Moorhead Daniel J

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:17:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Moorhead Daniel J

    3 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:15:38 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Lee Yoori

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:10 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air downgraded by BTIG Research

    BTIG Research downgraded Beyond Air from Buy to Neutral

    6/25/24 8:04:46 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on Beyond Air with a new price target

    Piper Sandler initiated coverage of Beyond Air with a rating of Overweight and set a new price target of $10.00

    7/28/23 7:37:57 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Leadership Updates

    Live Leadership Updates

    View All

    Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

    Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California. HAMILTON, Bermuda, June 01, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Jedidiah Monson, M.D. to the position of Chief Medical Officer, effective June 1, 2022. "We are excited to appoint Dr. Monson as

    6/1/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

    HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ:XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as Chief Financial Officer. Ms. Jones joins Beyond Cancer™ with over 30 years of international and operational financial leadership experience, including 20 years within the bioscience sector of BASF, a globally recognized chemical company. In her role as Senior Manager of Operational Accounting she was a key member of the implementation team responsible for the $4B acquisition of American Cyanamid. Follow

    5/17/22 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Expands Leadership Team with the Appointment of Dr. Andrew Colin to Chief Medical Officer

    Dr. Colin brings four decades of clinical experience in pediatric pulmonology to Beyond Air, with research spanning respiratory physiology, Cystic Fibrosis, and lung infections culminating in over 120 peer-reviewed publications and 250 global lectures As a board-certified pediatric pulmonologist, Dr. Colin has been an active member of Beyond Air's Scientific Advisory Board since 2013 Dr. Colin has participated in over 20 clinical trials, including studies sponsored by the National Institutes of Health, Genentech, GlaxoSmithKline, and the Cystic Fibrosis Foundation's Therapeutic Development Network GARDEN CITY, N.Y., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a c

    12/1/21 8:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Financials

    Live finance-specific insights

    View All

    Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the second quarter of its fiscal year 2025 ended September 30, 2024 on Monday, November 11, 2024 after the market closes. Conference Call & WebcastMonday, November 11th @ 4:30 PM ETDomestic: 1-877-407-0784International: 1-201-689-8560Conference ID: 13749670Webcast: A webcast of the live conference call can be accessed by visiting the Eve

    10/29/24 4:22:08 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

    LungFit® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit® PRO in hospitalized patients with community-acquired viral pneumonia, including COVID-19, at ECCMID 2022 Presented positive long-term safety data for high-concentration NO at PAS 2022 in infants hospitalized with bronchiolitis Presented positive updated interim data from the ongoing at-home LungFit® GO pilot study for nontuberculous mycobacterial lung disease at ATS 2022 Patient screening has begun for the Phase I trial of

    6/28/22 4:10:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

    GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that it has rescheduled the reporting of the financial results for its fiscal fourth quarter and year ended March 31, 2022 to Tuesday, June 28, 2022. The Company's management team will also host its quarterly conference call and webcast at 4

    6/14/22 4:30:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $XAIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Beyond Air Inc.

    SC 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    10/9/24 1:35:29 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    10/3/24 3:09:56 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Beyond Air Inc.

    SC 13G - Beyond Air, Inc. (0001641631) (Subject)

    3/7/24 12:29:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care